AutomedicationFrancoV1, Main, Exploration, bibRecord, 000258

Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial.

Identifieur interne : 000258 ( Main/Exploration ); précédent : 000257; suivant : 000259

Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial.

Auteurs : Rebecca Bauer [France] ; Emmanuelle Netzer [France] ; Claire Pintado [France] ; Catherine Capitant [France] ; Eric Cua [France] ; Nicolas Etien [France] ; Julien Fonsart [France] ; Gilles Pialoux [France] ; Christian Chidiac [France] ; Cédric Etienne [France] ; Véronique Doré [France] ; Laurence Meyer [France] ; Jean-Michel Molina [France]

Source :

AIDS and behavior [ 1573-3254 ] ; 2020.

RBID : pubmed:32350771

Descripteurs français

KwdFr :
- Adhésion au traitement médicamenteux (statistiques et données numériques), Adulte (MeSH), Agents antiVIH (administration et posologie), Agents antiVIH (usage thérapeutique), Comportement sexuel (MeSH), Homosexualité masculine (psychologie), Humains (MeSH), Infections à VIH (prévention et contrôle), Infections à VIH (traitement médicamenteux), Mâle (MeSH), Méthode en double aveugle (MeSH), Prophylaxie pré-exposition (méthodes), Rapports sexuels non protégés (statistiques et données numériques).
MESH :
- administration et posologie : Agents antiVIH.
- méthodes : Prophylaxie pré-exposition.
- prévention et contrôle : Infections à VIH.
- psychologie : Homosexualité masculine.
- statistiques et données numériques : Adhésion au traitement médicamenteux, Rapports sexuels non protégés.
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Agents antiVIH.
- Adulte, Comportement sexuel, Humains, Mâle, Méthode en double aveugle.

English descriptors

KwdEn :
- Adult (MeSH), Anti-HIV Agents (administration & dosage), Anti-HIV Agents (therapeutic use), Double-Blind Method (MeSH), HIV Infections (drug therapy), HIV Infections (prevention & control), Homosexuality, Male (psychology), Humans (MeSH), Male (MeSH), Medication Adherence (statistics & numerical data), Outcome Assessment, Health Care (MeSH), Pre-Exposure Prophylaxis (methods), Sexual Behavior (MeSH), Unsafe Sex (statistics & numerical data).
MESH :
- chemical , administration & dosage : Anti-HIV Agents.
- chemical , therapeutic use : Anti-HIV Agents.
- drug therapy : HIV Infections.
- methods : Pre-Exposure Prophylaxis.
- prevention & control : HIV Infections.
- psychology : Homosexuality, Male.
- statistics & numerical data : Medication Adherence, Unsafe Sex.
- Adult, Double-Blind Method, Humans, Male, Outcome Assessment, Health Care, Sexual Behavior.

Abstract

We assessed the coverage of sex acts by event-driven pre-exposure prophylaxis (ED-PrEP) over a 2-month period in 54 participants in the open label phase of the ANRS Ipergay trial. Participants received an electronic monitoring system device to record bottle openings. Self-questionnaires collected daily information on PrEP intake and sexual behavior. Intake was also estimated through returned pill counts. Full coverage of sex acts was defined as at least one pill taken both within 24 h before and within 48 h following sex. There was a strong correlation (r = - 0.92) between the number of bottle openings and returned pill counts. During the study, 42 participants (78%) practiced ED-PrEP and 12 (22%) daily PrEP with bottle openings at least 5 days/week whatever their sexual activity. Out of the 154 reported receptive anal sex acts, 81% were condomless: among them, PrEP coverage was hight: 97% among those practicing daily PrEP and 82% among those using ED-PrEP.

DOI: 10.1007/s10461-020-02890-6
PubMed: 32350771

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000176
to stream Main, to step Curation: 000176

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial.</title>
<author><name sortKey="Bauer, Rebecca" sort="Bauer, Rebecca" uniqKey="Bauer R" first="Rebecca" last="Bauer">Rebecca Bauer</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm SC10, Villejuif, France. rebecca.bauer@inserm.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm SC10, Villejuif</wicri:regionArea>
<placeName><settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Netzer, Emmanuelle" sort="Netzer, Emmanuelle" uniqKey="Netzer E" first="Emmanuelle" last="Netzer">Emmanuelle Netzer</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm SC10, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm SC10, Villejuif</wicri:regionArea>
<placeName><settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pintado, Claire" sort="Pintado, Claire" uniqKey="Pintado C" first="Claire" last="Pintado">Claire Pintado</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint-Louis, Maladies infectieuses, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Saint-Louis, Maladies infectieuses, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Capitant, Catherine" sort="Capitant, Catherine" uniqKey="Capitant C" first="Catherine" last="Capitant">Catherine Capitant</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm SC10, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm SC10, Villejuif</wicri:regionArea>
<placeName><settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cua, Eric" sort="Cua, Eric" uniqKey="Cua E" first="Eric" last="Cua">Eric Cua</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital de l'Archet, Maladies infectieuses, Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital de l'Archet, Maladies infectieuses, Nice</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Nice</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Etien, Nicolas" sort="Etien, Nicolas" uniqKey="Etien N" first="Nicolas" last="Etien">Nicolas Etien</name>
<affiliation wicri:level="3"><nlm:affiliation>ANRS, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>ANRS, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fonsart, Julien" sort="Fonsart, Julien" uniqKey="Fonsart J" first="Julien" last="Fonsart">Julien Fonsart</name>
<affiliation wicri:level="3"><nlm:affiliation>Biochimie Et Biologie Moléculaire, Hôpital Lariboisière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biochimie Et Biologie Moléculaire, Hôpital Lariboisière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pialoux, Gilles" sort="Pialoux, Gilles" uniqKey="Pialoux G" first="Gilles" last="Pialoux">Gilles Pialoux</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Tenon, Maladies infectieuses, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Tenon, Maladies infectieuses, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chidiac, Christian" sort="Chidiac, Christian" uniqKey="Chidiac C" first="Christian" last="Chidiac">Christian Chidiac</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital de la Croix Rousse, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital de la Croix Rousse, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Etienne, Cedric" sort="Etienne, Cedric" uniqKey="Etienne C" first="Cédric" last="Etienne">Cédric Etienne</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier de Grasse, Grasse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Hospitalier de Grasse, Grasse</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Grasse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dore, Veronique" sort="Dore, Veronique" uniqKey="Dore V" first="Véronique" last="Doré">Véronique Doré</name>
<affiliation wicri:level="3"><nlm:affiliation>ANRS, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>ANRS, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Meyer, Laurence" sort="Meyer, Laurence" uniqKey="Meyer L" first="Laurence" last="Meyer">Laurence Meyer</name>
<affiliation wicri:level="4"><nlm:affiliation>Inserm SC10, Université Paris Sud, Université Paris Saclay, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm SC10, Université Paris Sud, Université Paris Saclay, Villejuif</wicri:regionArea>
<placeName><settlement type="city">Villejuif</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint-Louis, Maladies infectieuses, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Saint-Louis, Maladies infectieuses, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32350771</idno>
<idno type="pmid">32350771</idno>
<idno type="doi">10.1007/s10461-020-02890-6</idno>
<idno type="wicri:Area/Main/Corpus">000176</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000176</idno>
<idno type="wicri:Area/Main/Curation">000176</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000176</idno>
<idno type="wicri:Area/Main/Exploration">000176</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial.</title>
<author><name sortKey="Bauer, Rebecca" sort="Bauer, Rebecca" uniqKey="Bauer R" first="Rebecca" last="Bauer">Rebecca Bauer</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm SC10, Villejuif, France. rebecca.bauer@inserm.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm SC10, Villejuif</wicri:regionArea>
<placeName><settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Netzer, Emmanuelle" sort="Netzer, Emmanuelle" uniqKey="Netzer E" first="Emmanuelle" last="Netzer">Emmanuelle Netzer</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm SC10, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm SC10, Villejuif</wicri:regionArea>
<placeName><settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pintado, Claire" sort="Pintado, Claire" uniqKey="Pintado C" first="Claire" last="Pintado">Claire Pintado</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint-Louis, Maladies infectieuses, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Saint-Louis, Maladies infectieuses, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Capitant, Catherine" sort="Capitant, Catherine" uniqKey="Capitant C" first="Catherine" last="Capitant">Catherine Capitant</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm SC10, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm SC10, Villejuif</wicri:regionArea>
<placeName><settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cua, Eric" sort="Cua, Eric" uniqKey="Cua E" first="Eric" last="Cua">Eric Cua</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital de l'Archet, Maladies infectieuses, Nice, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital de l'Archet, Maladies infectieuses, Nice</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Nice</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Etien, Nicolas" sort="Etien, Nicolas" uniqKey="Etien N" first="Nicolas" last="Etien">Nicolas Etien</name>
<affiliation wicri:level="3"><nlm:affiliation>ANRS, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>ANRS, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fonsart, Julien" sort="Fonsart, Julien" uniqKey="Fonsart J" first="Julien" last="Fonsart">Julien Fonsart</name>
<affiliation wicri:level="3"><nlm:affiliation>Biochimie Et Biologie Moléculaire, Hôpital Lariboisière, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biochimie Et Biologie Moléculaire, Hôpital Lariboisière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pialoux, Gilles" sort="Pialoux, Gilles" uniqKey="Pialoux G" first="Gilles" last="Pialoux">Gilles Pialoux</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Tenon, Maladies infectieuses, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Tenon, Maladies infectieuses, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chidiac, Christian" sort="Chidiac, Christian" uniqKey="Chidiac C" first="Christian" last="Chidiac">Christian Chidiac</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital de la Croix Rousse, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital de la Croix Rousse, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Etienne, Cedric" sort="Etienne, Cedric" uniqKey="Etienne C" first="Cédric" last="Etienne">Cédric Etienne</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier de Grasse, Grasse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Hospitalier de Grasse, Grasse</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Grasse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dore, Veronique" sort="Dore, Veronique" uniqKey="Dore V" first="Véronique" last="Doré">Véronique Doré</name>
<affiliation wicri:level="3"><nlm:affiliation>ANRS, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>ANRS, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Meyer, Laurence" sort="Meyer, Laurence" uniqKey="Meyer L" first="Laurence" last="Meyer">Laurence Meyer</name>
<affiliation wicri:level="4"><nlm:affiliation>Inserm SC10, Université Paris Sud, Université Paris Saclay, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm SC10, Université Paris Sud, Université Paris Saclay, Villejuif</wicri:regionArea>
<placeName><settlement type="city">Villejuif</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint-Louis, Maladies infectieuses, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Saint-Louis, Maladies infectieuses, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">AIDS and behavior</title>
<idno type="eISSN">1573-3254</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Anti-HIV Agents (administration & dosage)</term>
<term>Anti-HIV Agents (therapeutic use)</term>
<term>Double-Blind Method (MeSH)</term>
<term>HIV Infections (drug therapy)</term>
<term>HIV Infections (prevention & control)</term>
<term>Homosexuality, Male (psychology)</term>
<term>Humans (MeSH)</term>
<term>Male (MeSH)</term>
<term>Medication Adherence (statistics & numerical data)</term>
<term>Outcome Assessment, Health Care (MeSH)</term>
<term>Pre-Exposure Prophylaxis (methods)</term>
<term>Sexual Behavior (MeSH)</term>
<term>Unsafe Sex (statistics & numerical data)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adhésion au traitement médicamenteux (statistiques et données numériques)</term>
<term>Adulte (MeSH)</term>
<term>Agents antiVIH (administration et posologie)</term>
<term>Agents antiVIH (usage thérapeutique)</term>
<term>Comportement sexuel (MeSH)</term>
<term>Homosexualité masculine (psychologie)</term>
<term>Humains (MeSH)</term>
<term>Infections à VIH (prévention et contrôle)</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Mâle (MeSH)</term>
<term>Méthode en double aveugle (MeSH)</term>
<term>Prophylaxie pré-exposition (méthodes)</term>
<term>Rapports sexuels non protégés (statistiques et données numériques)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Pre-Exposure Prophylaxis</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Prophylaxie pré-exposition</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Homosexualité masculine</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Homosexuality, Male</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Medication Adherence</term>
<term>Unsafe Sex</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Adhésion au traitement médicamenteux</term>
<term>Rapports sexuels non protégés</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Double-Blind Method</term>
<term>Humans</term>
<term>Male</term>
<term>Outcome Assessment, Health Care</term>
<term>Sexual Behavior</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Comportement sexuel</term>
<term>Humains</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We assessed the coverage of sex acts by event-driven pre-exposure prophylaxis (ED-PrEP) over a 2-month period in 54 participants in the open label phase of the ANRS Ipergay trial. Participants received an electronic monitoring system device to record bottle openings. Self-questionnaires collected daily information on PrEP intake and sexual behavior. Intake was also estimated through returned pill counts. Full coverage of sex acts was defined as at least one pill taken both within 24 h before and within 48 h following sex. There was a strong correlation (r =  - 0.92) between the number of bottle openings and returned pill counts. During the study, 42 participants (78%) practiced ED-PrEP and 12 (22%) daily PrEP with bottle openings at least 5 days/week whatever their sexual activity. Out of the 154 reported receptive anal sex acts, 81% were condomless: among them, PrEP coverage was hight: 97% among those practicing daily PrEP and 82% among those using ED-PrEP.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32350771</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1573-3254</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>24</Volume>
<Issue>11</Issue>
<PubDate><Year>2020</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>AIDS and behavior</Title>
<ISOAbbreviation>AIDS Behav</ISOAbbreviation>
</Journal>
<ArticleTitle>Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial.</ArticleTitle>
<Pagination><MedlinePgn>3244-3251</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10461-020-02890-6</ELocationID>
<Abstract><AbstractText>We assessed the coverage of sex acts by event-driven pre-exposure prophylaxis (ED-PrEP) over a 2-month period in 54 participants in the open label phase of the ANRS Ipergay trial. Participants received an electronic monitoring system device to record bottle openings. Self-questionnaires collected daily information on PrEP intake and sexual behavior. Intake was also estimated through returned pill counts. Full coverage of sex acts was defined as at least one pill taken both within 24 h before and within 48 h following sex. There was a strong correlation (r =  - 0.92) between the number of bottle openings and returned pill counts. During the study, 42 participants (78%) practiced ED-PrEP and 12 (22%) daily PrEP with bottle openings at least 5 days/week whatever their sexual activity. Out of the 154 reported receptive anal sex acts, 81% were condomless: among them, PrEP coverage was hight: 97% among those practicing daily PrEP and 82% among those using ED-PrEP.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bauer</LastName>
<ForeName>Rebecca</ForeName>
<Initials>R</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0003-0683-4404</Identifier>
<AffiliationInfo><Affiliation>Inserm SC10, Villejuif, France. rebecca.bauer@inserm.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Netzer</LastName>
<ForeName>Emmanuelle</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Inserm SC10, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pintado</LastName>
<ForeName>Claire</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Hôpital Saint-Louis, Maladies infectieuses, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Capitant</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Inserm SC10, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cua</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Hôpital de l'Archet, Maladies infectieuses, Nice, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Etien</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>ANRS, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fonsart</LastName>
<ForeName>Julien</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Biochimie Et Biologie Moléculaire, Hôpital Lariboisière, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pialoux</LastName>
<ForeName>Gilles</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Hôpital Tenon, Maladies infectieuses, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chidiac</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Hôpital de la Croix Rousse, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Etienne</LastName>
<ForeName>Cédric</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Centre Hospitalier de Grasse, Grasse, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Doré</LastName>
<ForeName>Véronique</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>ANRS, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Meyer</LastName>
<ForeName>Laurence</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Inserm SC10, Université Paris Sud, Université Paris Saclay, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Molina</LastName>
<ForeName>Jean-Michel</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>Hôpital Saint-Louis, Maladies infectieuses, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>ANRS IPERGAY Study Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>N14036LR</GrantID>
<Agency>Institut National de la Santé et de la Recherche Médicale</Agency>
<Country></Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>AIDS Behav</MedlineTA>
<NlmUniqueID>9712133</NlmUniqueID>
<ISSNLinking>1090-7165</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018451" MajorTopicYN="N">Homosexuality, Male</DescriptorName>
<QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065129" MajorTopicYN="N">Pre-Exposure Prophylaxis</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012725" MajorTopicYN="Y">Sexual Behavior</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047568" MajorTopicYN="N">Unsafe Sex</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Event-drive</Keyword>
<Keyword MajorTopicYN="N">MSM</Keyword>
<Keyword MajorTopicYN="N">PrEP</Keyword>
<Keyword MajorTopicYN="N">Sex coverage</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32350771</ArticleId>
<ArticleId IdType="doi">10.1007/s10461-020-02890-6</ArticleId>
<ArticleId IdType="pii">10.1007/s10461-020-02890-6</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1011205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thigpen M, Kebaabetswe P, Smith D, Segolodi T, Soud F, Chillag K, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. In. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011.</Citation>
</Reference>
<Reference><Citation>Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1108524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00056-2</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1506273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lundgren JD, Battegay M, Behren G, De Wit S, Guaraldi G, Katlama C, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. Hiv Medicine. 2008;9(2):72–81.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1293.2007.00534.x</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>WHO. What’s the 2+1+1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: Update to WHO’s recommendation on oral PrEP. In; July 2019.</Citation>
</Reference>
<Reference><Citation>Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5(2):291–9.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0050028</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, et al. Predicting effective truvada (R) PrEP dosing strategies with a novel PK-PD model incorporating tissue active metabolites and endogenous nucleotides (EN). AIDS Res Hum Retroviruses. 2014;30:A60–A6060.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1089/aid.2014.5107a.abstract</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Inf Dis. 2014;14(9):820–9.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(14)70847-3</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, et al. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2018;5(2):E68–E78.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(17)30156-X</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mugo PM, Sanders EJ, Mutua G, van der Elst E, Anzala O, Barin B, et al. Understanding adherence to daily and intermittent regimens of oral HIV pre-exposure prophylaxis among men who have sex with men in Kenya. AIDS Behav. 2015;19(5):794–801.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1007/s10461-014-0958-x</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, et al. Daily and nondaily oral preexposure prophylaxis in men and transgender women who have sex with men: the human immunodeficiency virus prevention trials network 067/ADAPT study. Clin Infect Dis. 2018;66(11):1712–21.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix1086</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. Obstet Gynecol Surv. 2015;70(7):444–6.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1097/01.ogx.0000466878.37011.6f</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):14ra14.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3000391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Charreau I, et al. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. J Antimicrob Chemother. 2017;72(2):478–85.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkw412</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AARDEX Group, Ltd, Sion, Switzerland. MEMs software: https://www.aardexgroup.com . In.</Citation>
</Reference>
<Reference><Citation>Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016;32(1):32–433.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1089/aid.2015.0182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. JAIDS J Acquir Immun Def Syndr. 2014;66(3):340–8.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000000172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blum MR, Chittick GE, Begley JA, Zong J. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. 2007;47(6):751–9.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1177/0091270007300951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Team RC. R: A language and environment for statistical computing. In. 3.2.3 ed; 2015.</Citation>
</Reference>
<Reference><Citation>Di Ciaccio M, Fressard L, Sagaon-Teyssier L, Protiere C, Gatey C, Chas J, Cotte L, Castro DR, Meyer L, Molina JM, Préau M, Spire B. What are the situational and behavioral factors associated with condomless anal sex without PrEP in men who have sex with men? Results from the ANRS-IPERGAY trial. AIDS. 2020. https://doi.org/10.1097/QAD.0000000000002542 .</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000002542</ArticleId>
<ArticleId IdType="pubmed">32287072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Molina J, Prevenir ANRS Study G. Incidence of HIV-infection with daily or on-demand PrEP with TDF/FTC in Paris area. Update from the ANRS Prevenir Study. In; 2019 (IAS Mexico).</Citation>
</Reference>
<Reference><Citation>Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One. 2012;7(4):e33103.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vuylsteke B, Reyniers T, De Baetselier I, Nostlinger C, Crucitti T, Buyze J, et al. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. J Int AIDS Soc. 2019;22(10):e25407.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1002/jia2.25407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, et al. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. AIDS. 2018;32(15):2161–9.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000001939</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Provence-Alpes-Côte d'Azur</li>
<li>Rhône-Alpes</li>
<li>Île-de-France</li>
</region>
<settlement><li>Grasse</li>
<li>Lyon</li>
<li>Nice</li>
<li>Paris</li>
<li>Villejuif</li>
</settlement>
<orgName><li>Université Paris-Sud</li>
</orgName>
</list>
<tree><country name="France"><noRegion><name sortKey="Bauer, Rebecca" sort="Bauer, Rebecca" uniqKey="Bauer R" first="Rebecca" last="Bauer">Rebecca Bauer</name>
</noRegion>
<name sortKey="Capitant, Catherine" sort="Capitant, Catherine" uniqKey="Capitant C" first="Catherine" last="Capitant">Catherine Capitant</name>
<name sortKey="Chidiac, Christian" sort="Chidiac, Christian" uniqKey="Chidiac C" first="Christian" last="Chidiac">Christian Chidiac</name>
<name sortKey="Cua, Eric" sort="Cua, Eric" uniqKey="Cua E" first="Eric" last="Cua">Eric Cua</name>
<name sortKey="Dore, Veronique" sort="Dore, Veronique" uniqKey="Dore V" first="Véronique" last="Doré">Véronique Doré</name>
<name sortKey="Etien, Nicolas" sort="Etien, Nicolas" uniqKey="Etien N" first="Nicolas" last="Etien">Nicolas Etien</name>
<name sortKey="Etienne, Cedric" sort="Etienne, Cedric" uniqKey="Etienne C" first="Cédric" last="Etienne">Cédric Etienne</name>
<name sortKey="Fonsart, Julien" sort="Fonsart, Julien" uniqKey="Fonsart J" first="Julien" last="Fonsart">Julien Fonsart</name>
<name sortKey="Meyer, Laurence" sort="Meyer, Laurence" uniqKey="Meyer L" first="Laurence" last="Meyer">Laurence Meyer</name>
<name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name>
<name sortKey="Netzer, Emmanuelle" sort="Netzer, Emmanuelle" uniqKey="Netzer E" first="Emmanuelle" last="Netzer">Emmanuelle Netzer</name>
<name sortKey="Pialoux, Gilles" sort="Pialoux, Gilles" uniqKey="Pialoux G" first="Gilles" last="Pialoux">Gilles Pialoux</name>
<name sortKey="Pintado, Claire" sort="Pintado, Claire" uniqKey="Pintado C" first="Claire" last="Pintado">Claire Pintado</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000258 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000258 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    AutomedicationFrancoV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32350771
   |texte=   Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32350771" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AutomedicationFrancoV1

This area was generated with Dilib version V0.6.38.
Data generation: Mon Mar 15 15:24:36 2021. Site generation: Mon Mar 15 15:32:03 2021

	Serveur d'exploration sur l'automédication dans le monde francophone
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'automédication dans le monde francophone

Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial.

Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki